{
  "slug": "hiv-diagnosis-lifetime",
  "question": "What are the odds of being diagnosed with HIV in your lifetime?",
  "category": "health",
  "tags": [
    "relationships"
  ],
  "no_reliable_estimate": false,
  "perceived": {
    "description": "There is no standard tracker for perceived personal lifetime HIV risk, so the perceived side here is editorial intuition rather than polled data. Lay perception is distorted in two opposite directions at once. The 1980s-90s framing of HIV as a uniform death sentence still anchors the felt severity, even though a US adult diagnosed and treated today has a near-normal life expectancy on antiretroviral therapy. At the same time, personal probability is widely underestimated by the groups who actually carry elevated risk, via ordinary optimism bias and the sense that HIV is \"someone else's\" problem. The result is a population that overestimates how bad a diagnosis is and, in the higher-risk subgroups, underestimates how likely one is. The single national-average number is almost useless here: the same headline figure hides a 250-fold spread between subgroups.\n",
    "rough_estimate": "most people treat HIV as either near-zero personal risk or a uniform catastrophe; both miss the subgroup spread",
    "kind": "intuition"
  },
  "native": {
    "display": "0.95% lifetime risk of HIV diagnosis (~1 in 106), US 2010-2014",
    "numerator": 1,
    "denominator": 106,
    "unit": "lifetime risk",
    "population": "US general population, hypothetical birth cohort, CDC surveillance data 2010-2014"
  },
  "normalized": {
    "lifetime_us_adult": 0.0095,
    "display": "~1 in 106 lifetime (US average)",
    "log_value": -2.022,
    "assumptions": "Headline figure is the published, peer-reviewed Hess et al. 2017 estimate in Annals of Epidemiology: overall lifetime risk of an HIV diagnosis of 0.95% (95% CI 0.94-0.95), equivalently ~1 in 106, computed from CDC mortality, census, and HIV surveillance data for 2010-2014. The earlier, more frequently cited \"1 in 99\" figure is the same CDC research line at the prior 2009-2013 data window (presented at CROI 2016); the lifetime risk has declined monotonically — about 1 in 78 for 2004-2005, 1 in 99 for 2009-2013, and 1 in 106 for 2010-2014. We anchor on the published peer-reviewed window to keep the statistic, excerpt, and normalized number mutually consistent. Hess et al. compute lifetime risk as a birth-cohort cumulative probability (a hypothetical 10-million-birth cohort) assuming diagnosis rates stay constant. For HIV this is nearly identical to a from-age-18 US-adult lifetime basis, because almost no diagnosis risk accrues before adulthood and perinatal cases are a small fraction; the two bases are treated as equivalent here. The uncertainty band 0.008-0.013 brackets the post-2014 decline (new US infections fell to ~31,800 by 2022) on the low end and the 2004-2005-era figure on the high end. This national average is a scale marker only — the entry's point is the subgroup variance documented below, which ranges from roughly 1 in 524 (heterosexual men) to 1 in 2 (Black men who have sex with men).\n",
    "uncertainty": {
      "low": 0.008,
      "high": 0.013
    },
    "scope": "us_adult_lifetime"
  },
  "sources": [
    {
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5524204/",
      "title": "Lifetime Risk of a Diagnosis of HIV Infection in the United States",
      "publisher": "Annals of Epidemiology (Hess KL, Hu X, Lansky A, Mermin J, Hall HI)",
      "source_type": "peer_reviewed",
      "statistic": "Overall lifetime risk of an HIV diagnosis: 0.95% (95% CI 0.94-0.95), ~1 in 106. Lifetime risk 1 in 68 for males and 1 in 253 for females. Highest risk group MSM (1 in 6); lowest male heterosexuals (1 in 524). Data: 2010-2014.",
      "excerpt": "\"Overall, the lifetime risk of a diagnosis of HIV was 0.95% (95% CI: 0.94-0.95)... This means that to observe one HIV diagnosis, 106 (95% CI: 105-106) infants would need to be followed over a lifetime... The lifetime risk for males and females was 1 in 68 and 1 in 253, respectively... The risk group with the highest lifetime risk was MSM (1 in 6)... the lowest risk was among male heterosexuals (1 in 524).\"\n",
      "source_date": "2017-04-01",
      "source_accessed": "2026-06-21",
      "archive_url": "http://web.archive.org/web/20260402173945/https://pmc.ncbi.nlm.nih.gov/articles/PMC5524204/",
      "calculation_notes": "Hess et al. applied age-specific HIV-diagnosis probabilities from CDC surveillance data for 2010-2014 to a hypothetical cohort of 10 million live births to estimate cumulative lifetime risk. The published overall figure of 0.95% is used directly as the normalized value (0.0095), rounded display \"1 in 106\". No hazard compounding needed — it is already a lifetime cumulative probability. The male/female split (1/68, 1/253) arithmetically reproduces the overall figure at roughly the US 51/49 sex ratio: 0.51 × (1/68) + 0.49 × (1/253) ≈ 0.0094, an internal-consistency check on the extracted numbers.\n",
      "independence_note": "Hess et al. (CDC Division of HIV/AIDS Prevention) is the primary peer-reviewed analysis. The CDC HIV surveillance facts-stats page and the CDC PrEP efficacy page below are CDC programmatic outputs drawing on the same surveillance system; they are used as the current-incidence and intervention-efficacy cross-references, not as independent replications of the lifetime estimate.\n"
    },
    {
      "url": "https://www.cdc.gov/hiv/data-research/facts-stats/index.html",
      "title": "HIV Statistics — Facts & Stats",
      "publisher": "Centers for Disease Control and Prevention (CDC)",
      "source_type": "govt_report",
      "statistic": "31,800 estimated new HIV infections in the US in 2022; 37,981 new diagnoses. 67% of new infections among gay, bisexual, and other men who have male-to-male sexual contact; 22% heterosexual contact; 7% people who inject drugs. The South accounted for 49% of new infections (rate 506.5 per 100,000) vs 131.6 in the Midwest.",
      "excerpt": "\"There were 31,800 estimated new HIV infections in the US in 2022... Gay, bisexual, and other men who reported male-to-male sexual contact accounted for 67% (21,400) of the 31,800 estimated new HIV infections... 22% were among people who reported heterosexual contact... 7% were among people who inject drugs... In 2022, the South accounted for nearly half (49%) of the 31,800 estimated new HIV infections.\"\n",
      "source_date": "2024-04-22",
      "source_accessed": "2026-06-21",
      "calculation_notes": "Used as the current-incidence cross-check on the 2010-2014 lifetime projection. The decline to ~31,800 new infections per year by 2022 (from ~37,000-40,000 in the early 2010s) supports placing the lifetime point estimate at the lower end of the historical 1-in-78-to-1-in-106 range and informs the uncertainty band. The transmission-category and regional shares motivate the personal_factor_multipliers and regional_breakdown.\n"
    },
    {
      "url": "https://www.cdc.gov/hivnexus/hcp/prep/index.html",
      "title": "Pre-Exposure Prophylaxis (PrEP) — HIV Nexus, Clinical Resources",
      "publisher": "Centers for Disease Control and Prevention (CDC)",
      "source_type": "govt_report",
      "statistic": "When taken as prescribed, both oral and injectable PrEP reduce the risk of getting HIV from sex by about 99%. Oral PrEP reduces the risk of getting HIV from injection drug use by at least 74% when taken as prescribed.",
      "excerpt": "\"When taken as prescribed, both oral and injectable PrEP reduce the risk of getting HIV from sex by about 99%... Oral PrEP has also been shown to reduce the risk of getting HIV from injection drug use by at least 74%, when taken as prescribed.\"\n",
      "source_date": "2026-04-30",
      "source_accessed": "2026-06-21",
      "archive_url": "http://web.archive.org/web/20260616164930/https://www.cdc.gov/hivnexus/hcp/prep/index.html",
      "calculation_notes": "The ~99% sexual-acquisition reduction is the basis for the PrEP protective multiplier of ~0.01 (a roughly 99% reduction in sexual-route risk for adherent users). The 74% injection-route reduction is reported separately. \"As prescribed\" is load-bearing: real-world effectiveness is lower where adherence lapses, so the 0.01 multiplier is a best-case figure for consistent daily/on-time use.\n"
    },
    {
      "url": "https://www.aidsmap.com/news/feb-2016/major-disparities-persist-lifetime-risk-hiv-diagnosis-us",
      "title": "Major disparities persist in lifetime risk of HIV diagnosis in the US",
      "publisher": "aidsmap / NAM (Liz Highleyman)",
      "source_type": "news_article",
      "statistic": "Overall lifetime HIV-diagnosis risk fell from about 1 in 78 (2004-2005) to 1 in 99 (2009-2013). Black gay/bisexual men 1 in 2; Latino gay men 1 in 4; white gay men 1 in 11. All MSM 1 in 6. Lifetime risk ranged from 1 in 670 (North Dakota) to 1 in 13 (Washington, DC).",
      "excerpt": "\"The researchers found that the overall lifetime risk of an HIV-positive diagnosis was lower than it was a decade ago, falling from about 1 in 78 during 2004-2005 to 1 in 99 during 2009-2013... The lifetime risk estimate is the cumulative probability of being diagnosed with HIV from birth to death, assuming diagnosis rates remain constant.\"\n",
      "source_date": "2016-02-24",
      "source_accessed": "2026-06-21",
      "archive_url": "http://web.archive.org/web/20260215013728/https://www.aidsmap.com/news/feb-2016/major-disparities-persist-lifetime-risk-hiv-diagnosis-us",
      "calculation_notes": "Secondary source covering the CROI 2016 presentation of the same CDC research line at the earlier 2009-2013 data window, where the overall figure was the widely cited \"1 in 99\". Used only to document the 1-in-99 historical framing and the time trend; the 2009-2013 subgroup figures (e.g. Latino MSM 1 in 4, DC 1 in 13) are NOT mixed into the published 2010-2014 source block above. Non-authoritative type; the three CDC/peer-reviewed sources carry the entry's authority requirement.\n"
    }
  ],
  "comparison_anchors": [
    {
      "label": "Suicide (lifetime, US adult)",
      "lifetime_us_adult": 0.00827
    },
    {
      "label": "Tuberculosis death (lifetime, global adult)",
      "lifetime_us_adult": 0.0092
    },
    {
      "label": "Type 2 diabetes death (lifetime, US adult)",
      "lifetime_us_adult": 0.075
    },
    {
      "label": "Major depression (lifetime, US adult)",
      "lifetime_us_adult": 0.206
    }
  ],
  "regional_breakdown": [
    {
      "region": "US average",
      "probability": 0.0095,
      "notes": "Hess et al. 2017, overall lifetime risk of HIV diagnosis, 2010-2014 data (0.95%)."
    },
    {
      "region": "Highest-incidence Southern states",
      "probability": 0.018,
      "notes": "The South carries the highest burden: 49% of the 31,800 new US infections in 2022 (CDC), with a 2022 diagnosis rate of 506.5 per 100,000 vs 131.6 in the Midwest. The highest published state lifetime risks (mostly Southern) were Maryland (1 in 56), Georgia (1 in 57), Florida and Louisiana (1 in 58); ~1 in 56 (≈0.018) marks those top states, not a South-wide average, which is lower."
    },
    {
      "region": "Washington, DC",
      "probability": 0.059,
      "notes": "Highest in the US in the published 2010-2014 analysis at 1 in 17 (≈0.059); the earlier 2009-2013 window placed DC at 1 in 13. Reflects a dense urban epidemic, not a typical state."
    },
    {
      "region": "Lowest-incidence states (e.g. Montana, North Dakota)",
      "probability": 0.0015,
      "notes": "Published 2010-2014 range bottomed at 1 in 674 (Montana, ≈0.0015); the 2009-2013 window placed North Dakota at 1 in 670. Two-plus orders of magnitude below DC."
    }
  ],
  "personal_factor_multipliers": [
    {
      "factor": "Men who have sex with men (MSM)",
      "multiplier": 17,
      "notes": "Hess et al.: MSM lifetime risk 1 in 6 (~0.167) vs overall ~1 in 106 (0.0095), ratio ≈ 17.5. MSM is the highest-risk transmission group; male heterosexuals are the lowest at 1 in 524."
    },
    {
      "factor": "Black men who have sex with men",
      "multiplier": 53,
      "notes": "Hess et al.: Black MSM lifetime risk 1 in 2 (~0.50) vs overall ~1 in 106, ratio ≈ 53. The single highest-risk subgroup in the analysis — a roughly 1-in-2 lifetime chance, driven by network and access disparities, not individual behavior frequency."
    },
    {
      "factor": "Hispanic/Latino men who have sex with men",
      "multiplier": 21,
      "notes": "Hess et al. (published 2010-2014): Hispanic/Latino MSM lifetime risk 1 in 5 (0.20) vs overall ~1 in 106, ratio ≈ 21. (The earlier 2009-2013 CROI window reported 1 in 4 for Latino MSM.)"
    },
    {
      "factor": "People who inject drugs",
      "multiplier": 3.5,
      "notes": "Hess et al.: lifetime risk 1 in 26 for women who inject drugs (~0.038) and 1 in 43 for men (~0.023) vs overall ~1 in 106. Ratio ≈ 4 (women) and ≈ 2.5 (men); ~3.5 is a midpoint. Injection-route HIV risk is reducible by ~74% with PrEP (CDC) and further by sterile-equipment access."
    },
    {
      "factor": "Black women (vs overall)",
      "multiplier": 2,
      "notes": "Hess et al.: Black women lifetime risk 1 in 54 (~0.0185) vs overall ~1 in 106, ratio ≈ 2. The racial disparity among women specifically is starker — Black women 1 in 54 vs white women 1 in 941, roughly 17-fold — but that within-women gap is discussed in the caveats rather than encoded here, since this multiplier is relative to the overall baseline like every other factor."
    },
    {
      "factor": "Consistent condom use",
      "multiplier": 0.2,
      "notes": "Protective. Meta-analyses of serodiscordant couples find consistent condom use reduces sexual HIV transmission by roughly 80% (a ~0.2 multiplier on the sexual-acquisition route); CDC describes condoms as highly effective when used correctly every time. Less protective than PrEP, and route-specific."
    },
    {
      "factor": "PrEP taken as prescribed",
      "multiplier": 0.01,
      "notes": "Protective. CDC: oral/injectable PrEP reduces the risk of getting HIV from sex by about 99% when taken as prescribed (a ~0.01 multiplier on the sexual route). Best-case figure for consistent adherence; real-world effectiveness drops when doses are missed. Reduces injection-route risk by at least 74%."
    }
  ],
  "short_label": "HIV diagnosis",
  "myth_framing": "underrated",
  "outcome_severity": "serious_harm",
  "exposure_pattern": "recurring",
  "outcome_type": "chronic_illness",
  "valence": "negative",
  "caveats": "The headline 0.95% (~1 in 106) is a national-average lifetime risk projected from 2010-2014 CDC surveillance assuming diagnosis rates hold constant — not a current snapshot, and the rate has continued to decline (US new infections fell to ~31,800 by 2022). The far more important caveat is heterogeneity: the average is the least informative number in this entry. Lifetime risk spans more than two orders of magnitude across subgroups — roughly 1 in 524 for heterosexual men, 1 in 2 for Black men who have sex with men — and across geography, from about 1 in 674 in the lowest-incidence states to about 1 in 17 in Washington, DC. The published paper measures the probability of a diagnosis, which lags actual infection; undiagnosed infections are not fully captured. Race/ethnicity multipliers reflect structural and network factors (testing access, treatment-as-prevention coverage, partner-pool prevalence), not individual behavior, and should be read as epidemiological strata rather than personal traits. The protective multipliers (condoms ~0.2, PrEP ~0.01) are route-specific and assume correct, consistent use; the PrEP figure is a best-case adherence number. With modern antiretroviral therapy a diagnosed US adult who stays in care has a near-normal life expectancy and is effectively non-infectious (undetectable = untransmittable), which is why this entry is filed as a chronic illness rather than a fatal outcome.\n",
  "quality_score": {
    "d1": 5,
    "d2": 5,
    "d3": 5,
    "d4": 4,
    "d5": 4,
    "d6": 5,
    "d7": 4,
    "d8": 5,
    "avg": 4.625,
    "scored_by": "claude-code-8d",
    "scored_at": "2026-06-21",
    "methodology_version": "1.2"
  },
  "reviewer": "8d-eval-2026-06-21",
  "last_reviewed": "2026-06-21",
  "reviewed": true,
  "generated_at": "2026-06-21",
  "image": {
    "alt": "An abstract awareness ribbon loop rendered as a single continuous line beside a faint grid, flat vector illustration in muted tones."
  },
  "attribution": "Likelier — https://likelier.app",
  "license": "https://creativecommons.org/licenses/by-sa/4.0/",
  "support": "https://buymeacoffee.com/kgluszczyk?via=likelier&utm_content=api-fear-single",
  "canonical_url": "https://likelier.app/hiv-diagnosis-lifetime"
}